CJC-1295 + Ipamorelin: Benefits, Dosing & Side Effects

CJC-1295 and Ipamorelin are two prescription peptides that are usually injected together. Each one prompts the pituitary gland to release more of the body’s own growth hormone, and each does it through a different receptor. Most people look into the pairing for better sleep and recovery, and some for a slow change in body composition.

Neither peptide has an FDA approval, and the research behind them is thin compared with an approved medication. This guide covers what patients report and the side effects to know about. It also sets the pairing beside Tesamorelin and Sermorelin and explains the lab and follow-up schedule at Medrein.

What is CJC-1295?#

CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH). GHRH is the signal the hypothalamus sends to the pituitary gland when it is time to release growth hormone. CJC-1295 binds the same receptor, so the pituitary releases growth hormone of its own. The liver then raises its output of IGF-1, the hormone that carries much of growth hormone’s effect on fat and muscle.

Because the pituitary still makes the hormone, the body’s own feedback system stays in charge. When levels rise far enough, release slows down. That is the main difference between a GHRH peptide and injecting synthetic growth hormone (HGH), which bypasses the pituitary entirely. It is also why an IGF-1 level is checked before the first injection of our CJC-1295 program, and again later to see how you are responding.

CJC-1295 with DAC and without DAC#

CJC-1295 comes in two forms, and they behave very differently. The version without DAC (also called Modified GRF 1-29) clears the body in about 30 minutes. It produces a short pulse of growth hormone that resembles the body’s natural rhythm, so it is given once or twice a day.

The version with DAC (Drug Affinity Complex) binds to proteins in the blood, which keeps it circulating far longer. In a 2006 study in healthy adults, a single injection of the DAC form raised growth hormone and IGF-1 for days, and the study authors estimated its half-life at roughly six to eight days. That is why the DAC form is given only once or twice a week.

Dr. Mikki most often prescribes CJC-1295 without DAC, paired with Ipamorelin. The DAC form is more often used on its own, for patients who prefer fewer injections.

How CJC-1295 and Ipamorelin work together#

Ipamorelin is a growth hormone secretagogue. It triggers growth hormone release through the ghrelin receptor, which is a separate pathway from the GHRH receptor that CJC-1295 uses. When both receptors are activated at the same time, the pituitary releases a larger pulse than either peptide produces alone. That combined effect is the reason the two are prescribed as a pair.

Ipamorelin is also selective. Early laboratory research described it as the first selective secretagogue, because it released growth hormone without the rise in cortisol and prolactin that older peptides in its class caused. That research was done in animals, so it describes how the molecule acts and does not predict any one person’s results.

Benefits patients report on CJC-1295 and Ipamorelin#

The changes patients describe on this pairing follow the role growth hormone plays in the body. Growth hormone is released mostly during deep sleep, and it supports muscle repair and fat metabolism. These are reported experiences, and most of them have not been tested in large controlled trials.

• Sleep quality is usually the first change patients notice, often within the first two weeks.
• Recovery from training tends to feel quicker, with less soreness afterwards.
• Energy through the day is often steadier, with fewer afternoon slumps.
• Body composition can shift over months, with a little more lean muscle and less body fat, particularly for people who train.
• Skin quality may improve as collagen production rises.

Many people ask whether Ipamorelin reduces belly fat. Growth hormone does help the body break down stored fat, and some patients see a smaller waist over time. The peptide with trial evidence specifically for visceral belly fat is Tesamorelin, which is covered further down. Results may vary with age and training habits.

Is CJC-1295 FDA-approved?#

No. Neither CJC-1295 nor Ipamorelin is FDA-approved for any use. When a physician prescribes them, the prescription is off-label and is filled by a compounding pharmacy. Medrein uses reputable compounding pharmacies only.

The FDA has looked at both peptides closely. In 2023 it placed them in category 2 of its compounding review, the group of bulk substances it says may present significant safety risks. For both, the agency cites the chance of an immune reaction to the peptide or to impurities made during manufacturing. For CJC-1295 it also notes reported serious adverse events, including a raised heart rate and a whole-body flushing reaction, and says clinical data are limited. The CJC-1295 nomination was later withdrawn. Ipamorelin is still listed in category 2 for large outsourcing facilities.

If you compete in tested sport, these peptides are off the table. The WADA Prohibited List bans GHRH analogs and growth hormone secretagogues at all times, and it names CJC-1295, Ipamorelin, Sermorelin and Tesamorelin.

Side effects and who should not take it#

Most side effects reported with this pairing are mild and tend to follow the amount given. That is one reason the dose starts low and changes only at follow-up.

• Injection-site reactions such as redness, itching or mild swelling.
• Temporary water retention, which can show up as puffiness or mild joint discomfort.
• Increased hunger, which comes from the Ipamorelin side of the pairing.
• Tingling or numbness in the hands, headaches or tiredness, which are less common.
• Flushing or a faster heartbeat, which the FDA lists among the reported serious events and which you should report straight away.
• Changes in blood sugar, which is why glucose and HbA1c are part of the baseline labs.

CJC-1295 and Ipamorelin are not used in anyone with active cancer or a recent history of it, during pregnancy or breastfeeding, or in anyone under 18. They are also not used with active diabetic retinopathy, certain pituitary tumors, acute critical illness or a known allergy to a peptide component. A consultation with a licensed provider decides whether you are a candidate. The injection itself takes seconds, and most people carry on with their day.

CJC-1295/Ipamorelin vs Tesamorelin#

All three GHRH peptides prompt the pituitary to release your own growth hormone. What separates CJC-1295 with Ipamorelin from Tesamorelin comes down to three points:

• Receptors. The pairing works through two receptors at once. Tesamorelin works through the GHRH receptor alone.
• Evidence and approval. Tesamorelin is FDA-approved for one use, reducing excess abdominal fat in adults with HIV-associated lipodystrophy, and its trial measured visceral fat on CT scans. CJC-1295 and Ipamorelin have no approval and far less clinical data.
• Goal. Tesamorelin is usually considered when visceral belly fat is the target. The pairing is more often chosen for sleep and recovery, with body composition changing over time.

Some patients start on one and later move to the other, and that call rests on follow-up labs and how their goals change. Our Tesamorelin guide covers its label, side effects and results timeline in full. Sermorelin is the third option, a shorter GHRH fragment given in the evening.

How treatment works at Medrein#

CJC-1295 with Ipamorelin is one of the peptides in our GHRH peptides category, and the steps are the same whichever one you end up on.

Consultation and baseline labs#

It starts with a consultation. Dr. Mikki, a board-certified MD, takes your medical history, asks about your goals and does a physical exam. She then orders baseline bloodwork before anything is prescribed:

• A metabolic panel with fasting glucose and HbA1c
• A lipid profile
• A complete blood count (CBC)
• Thyroid function
• Testosterone
• IGF-1, the growth hormone marker every later result is compared against

Those results decide whether a growth hormone peptide makes sense for you, which form of CJC-1295 fits, and whether Ipamorelin is added. Dr. Mikki will tell you plainly if the labs point somewhere else.

Injection timing and schedule#

Both peptides are small subcutaneous injections, most often into the fatty tissue of the abdomen, and you give them yourself at home once you have been shown how. With the form without DAC, the pairing is injected once or twice a day, typically before bed and sometimes after a workout. Bedtime lines up with the body’s largest natural release of growth hormone during deep sleep. The DAC form is injected once or twice a week.

Dr. Mikki sets the amount in each injection herself and starts conservatively, so no dose numbers are published here. A figure taken from a forum or a vendor website is not a safe starting point.

Follow-up and how long treatment runs#

The first follow-up comes at two to four weeks, to check how you are sleeping, how you feel and whether any side effects have appeared. Further reviews run across the first three months, with repeat labs, and after that a check every few months. The dose is adjusted at these visits against your IGF-1 level and your response, and treatment is lowered or paused if you are not tolerating it. How long you continue is a decision you make with Dr. Mikki based on those results.

How long CJC-1295 and Ipamorelin take to work#

Changes arrive gradually and in a fairly predictable order. Sleep is usually the first thing patients describe changing, within one to two weeks. Energy and recovery from exercise tend to follow over weeks two to four, with mood often lifting around weeks three to four.

Early changes in body composition and skin quality tend to appear around weeks six to eight in people who respond. Between weeks eight and twelve those changes more often become visible. The fuller change is described over four to six months of consistent use. How much you see depends on your starting labs and your age, and sleep and training habits play a part too. Results may vary.

Getting started with CJC-1295 and Ipamorelin at Medrein#

CJC-1295 with Ipamorelin is an off-label pairing with a modest evidence base and a timeline measured in months. It tends to suit adults who want better sleep and recovery and are willing to keep up with labs and follow-up visits. It is not an option for anyone subject to sport drug testing, and regular training helps the results along.

If you want to know whether it is an option for you, or whether Tesamorelin or Sermorelin would fit better, book a consultation at our Southlake clinic. Dr. Mikki will go through your history and your labs and give you a straight answer.